Pricing Log in Create free account

Bicycle Therapeutics PLC Sponsored ADR (BCYC) vs Keros Therapeutics, Inc. (KROS)

Bicycle Therapeutics PLC Sponsored ADR and Keros Therapeutics, Inc. are both Biotechnology companies. Bicycle Therapeutics PLC Sponsored ADR and Keros Therapeutics, Inc. are of similar size ($183.7M and $182.5M). Bicycle Therapeutics PLC Sponsored ADR grew revenue faster over the last twelve months: 194.8% against −76.4%. Keros Therapeutics, Inc. has the higher net margin (−112.2% vs −169.8%) and the higher return on invested capital (−233.2% vs −279.8%). Across the 17 metrics below, Keros Therapeutics, Inc. leads on 13 and Bicycle Therapeutics PLC Sponsored ADR on 4.

Valuation

Metric BCYC KROS Biotechnology median
P/E n/m n/m 10.60
P/S 3.02 3.38 9.40
P/B 0.50 0.67 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA 1.28 1.02 0.66
EV/Sales (2.35) (1.33) 9.02
Earnings yield (56.22%) (30.02%) (32.88%)
Free cash flow yield (70.08%) (25.93%) (23.13%)

Profitability

Metric BCYC KROS Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin (189.43%) (133.16%) 0.00%
Net margin (169.75%) (112.18%) 0.00%
Free cash flow margin (211.95%) (87.73%) 0.00%
Return on equity (25.24%) (12.56%) (51.96%)
Return on assets (21.30%) (11.76%) (46.06%)
Return on invested capital (279.76%) (233.22%) 0.00%

Growth

Metric BCYC KROS Biotechnology median
Revenue growth (TTM) 194.75% (76.37%) 6.76%
EPS growth (last fiscal year) (8.97%) 146.00% 29.88%
Revenue growth, 5-year CAGR 47.52% 89.45% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BCYC KROS Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 12.09 18.14 4.97
Net debt to EBITDA 2.61 (4.16) 1.01

Dividend

Metric BCYC KROS Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric BCYC KROS Biotechnology median
Market cap 182.52m 183.68m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack